GBS infections are most prevalent among newborns, and of 2,000 or so infants who contract the disease, 4 to 6 percent die, according to the CDC. And about 25 percent of pregnant people have the capacity to pass on the bacteria to their infant, Pfizer said in a Sept. 7 news release.
The vaccine candidate, named GBS6, “could help protect newborns from the serious illnesses caused by this disease like meningitis, pneumonia and sepsis,” Annaliesa Anderson, PhD, Pfizer’s senior vice president and head of vaccine research and development, said in the statement. “[A GBS vaccine is] a critical global public health need.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
